At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 592 enrolled
Drug / intervention
1=Etanercept +1 moredrug
Likely dose
1=Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating 1=Etanercept and 2=Clobetasol propionate foam for Psoriasis. Completed, enrolled 592 participants.
Detailed Summary
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by PASI 75 at Week 12.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedNov 2010
Primary CompletionOct 2011
Study CompletionDec 2011
TodayJul 2026
First PostedNov 5, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.7 years ago
Interventions
1=Etanerceptdrug
50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
2=Clobetasol propionate foamdrug
0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses